During the last session, Taysha Gene Therapies Inc (NASDAQ:TSHA)’s traded shares were 1.32 million, with the beta value of the company hitting 0.87. At the end of the trading day, the stock’s price was $1.69, reflecting an intraday loss of -0.59% or -$0.01. The 52-week high for the TSHA share is $4.32, that puts it down -155.62 from that peak though still a striking 29.59% gain since the share price plummeted to a 52-week low of $1.19. The company’s market capitalization is $346.45M, and the average trade volume was 2.30 million shares over the past three months.
Taysha Gene Therapies Inc (TSHA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.09. TSHA has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.1.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Taysha Gene Therapies Inc (TSHA) registered a -0.59% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.59% in intraday trading to $1.69, hitting a weekly high. The stock’s 5-day price performance is 6.29%, and it has moved by 7.64% in 30 days. Based on these gigs, the overall price performance for the year is -43.67%.
The consensus price target of analysts on Wall Street is $8.5, which implies an increase of 80.12% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $44 respectively. As a result, TSHA is trading at a discount of -2503.55% off the target high and -195.86% off the low.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
In the rating firms’ projections, revenue will decrease -29.32% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.48M as predicted by 10 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to 1.77M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 3.41M and 1.11M respectively. In this case, analysts expect current quarter sales to shrink by -56.55% and then jump by 58.94% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -63.99%. While earnings are projected to return -0.62% in 2025, the next five years will return -0.24% per annum.
TSHA Dividends
Taysha Gene Therapies Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 18.8 million shares, is of RTW INVESTMENTS, LP’s that is approximately 8.075% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $42.11 million.
